Pfizer, Valneva plan to move Lyme disease vaccine candidate into Phase 3 trialMarket Watch • 04/26/22
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine CandidateBusiness Wire • 04/26/22
Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMedGlobeNewsWire • 04/26/22
Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine CandidateGlobeNewsWire • 04/25/22
Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 VaccineGlobeNewsWire • 04/14/22
Valneva SE (VALN) CEO Thomas Lingelbach on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Valneva Announces Filing of 2021 Universal Registration Document and US Form 20-FGlobeNewsWire • 03/24/22
Valneva Announces Renewal of the Term of Office of its Management Board MembersGlobeNewsWire • 03/16/22
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 03/08/22
Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001GlobeNewsWire • 03/01/22
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001GlobeNewsWire • 02/25/22
Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine DevelopmentGlobeNewsWire • 02/21/22
Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving ForwardBenzinga • 02/04/22
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine CandidateGlobeNewsWire • 02/04/22
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 GuidanceGlobeNewsWire • 02/03/22
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 01/31/22